Eli Lilly has amassed a stockpile of soon-to-be-launched drugs and related materials, primarily its oral GLP-1 candidate ...

As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...

Pfizer ends commercialization of Beqvez hemophilia B gene therapy. CEO Kim Phelan of Coalition for Hemophilia B expresses ...

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

Exelixis and Neurocrine each announce $500M share buybacks; Cosette buys Mayne for $430M; MeiraGTx seeks UK approval for blindness gene therapy; Hookipa ends Poolbeg talks.

Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...

A meet­ing of CDC vac­cine ad­vi­sors has been post­poned, ac­cord­ing to a se­nior HHS of­fi­cial. “The ACIP meet­ing will ...

Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four ...

Mother took Evrysdi for SMA before birth; baby later received Zolgensma. Dr. Richard Finkel at St. Jude led study showing no ...

The proxy filing for Accolade, a healthcare navigator that connects workers to care on behalf of their employers, agreed to ...

Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.

Charles River Labs beats Q4 estimates, Theratechnologies resumes Egrifta SV distribution, FDA greenlights BCG alternative, ...